The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials
Abstract
Aside from allogeneic transplantation, the current standard-of-care approach for higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) remains monotherapy with a hypomethylating agent (HMA), including azacitidine, decitabine, or oral decitabine/cedazuridine. Many attempts using HMA-based combinations have failed to improve upon HMA monotherapy. Although promising efficacy was observed in early-phase clinical trials with several agents, subsequent randomized phase 3 trials failed to confirm improvements in complete response rates or overall survival. In this review, we discuss lessons learned from the recently reported negative trials of azacitidine in combination with eprenetapopt (APR-246), magrolimab, pevonedistat, sabatolimab, tamibarotene, and venetoclax. First, we make a case for emphasizing biological classification rather than disease risk status alone to select patients for HR-MDS trials. Second, we argue that patients with TP53-inactivated MDS and chronic myelomonocytic leukemia should be treated in dedicated clinical trials. Alternatively, if TP53-inactivated MDS is included in HR-MDS trials, then randomization stratification by TP53 inactivation status should be considered. Third, we caution against ignoring signals of excessive toxicity and premature discontinuation of investigational agent observed in early-phase trials. Fourth, we show that the International Working Group (IWG) 2006 response criteria, long used in HR-MDS trials, can both overestimate and underestimate the true therapeutic benefit. Instead, we advocate for using the IWG 2023 response criteria to better capture clinically meaningful benefits in HR-MDS. Lastly, we emphasize the need for the scientific community to access patient-level data and samples from failed phase 3 trials in an efficient and expedited fashion to inform the development of subsequent trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01613-1 · Cited by 4,274
Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H.-M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., et al. (2022) · Blood · doi:10.1182/blood.2022015850 · Cited by 2,945
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012971 · Cited by 2,900
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Bernard, E., Tuechler, H., Greenberg, P. L., Hasserjian, R. P., Arango Ossa, J. E., Nannya, Y., Devlin, S. M., Creignou, M., Pinel, P., Monnier, L., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200008 · Cited by 867
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776
Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1008-z · Cited by 648
Research works printed but not linked: 2
- Bernard, 2020, Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes, Nat Med, 26, 1549, 10.1038/s41591-020-1008-z · DOI · Paper page
- Sallman, 2023, Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study, J Clin Oncol, 41, 2815, 10.1200/JCO.22.01794 · DOI · Paper page
Cited by
A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions
Bewersdorf, J. P., Mina, A. A., Stahl, M. F., & Zeidan, A. M. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01141-2 · Cited by 16
Self-citationZeidan, A. M., Aakko, S., Stahl, M. F., Bewersdorf, J. P., Bono, P., Huttunen, T., Jalkanen, J., Louramo, E., Nimba, A., & Williamson, J. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2640238 · Cited by 3
“Consistent with this, Stahl and Zeidan [29] argue that eligibility frameworks dominated by risk scores and blast cutoffs can mask disease biology-driven treatment effects, supporting prospective molecular stratification (and, where appropriate, caps or enrichment strategies) in confirmatory HR-MDS…”
InfluentialSelf-citationPharmacologic progress in higher-risk MDS: an uphill battle
Mina, A. A., & Zeidan, A. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2644384 · Cited by 1
“This raises possibility that a more biologically enriched approach, particularly focusing on patients with 10–19% blasts (or MDS/AML as defined by the ICC) may yield more meaningful clinical benefit from the addition of VEN to AZA [136,190].”
Self-citationQin, S., Peng, R., Zhang, G., Yan, S., Xiao, J., Liu, Z., Tan, Z., Xie, Q., Li, S., Luo, W., et al. (2026) · Smart Molecules · doi:10.1002/smo2.70089 · Cited by 2
Shah, M. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.01.012
Metadata
- Authors
- Stahl, M., & Zeidan, A. M.
- Affiliations
- Yale Cancer Center (US)
- Corresponding author
- Zeidan, Amer M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2026-02-19
- Volume
- 147
- Issue
- 8
- Pages
- 811-820
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W4415767294
- Cited by
- 14
- References
- 64
- Citations by year
- 2026: 14
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- high-risk myelodysplastic syndrome, drug development, hypomethylating agents, azacitidine, APR-246, magrolimab, pevonedistat, tamibarotene, venetoclax, p53 inactivation, chronic myelomonocytic leukemia, taxonomy (general classification scheme)
- MeSH terms
- Drug Development, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Humans, Myelodysplastic Syndromes, Clinical Trials, Phase III as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials. https://app.cochat.ai/papers/10.1182/blood.2025029727
- The paper
- Stahl, M., & Zeidan, A. M. (2026). The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials. Blood. https://doi.org/10.1182/blood.2025029727
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.